Alimentary pharmacology & therapeutics · 2025
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osty Mathilde, Altwegg Romain, Serrero Mélanie, Benezech Alban, Lecomte Albane, Cadiot Guillaume, Vuitton Lucine, Wampach Anne, Nancey Stéphane, Buisson Anthony, le Berre Catherine, Rouillon Clea, Gilletta Cyrielle, Goutorbe Felix, Fumery Mathurin, Hammoudi Nassim, Caillo Ludovic, Vidon Mathias, Arab Nadia, Sickersen Gaelle, Cavicchi Maryan, Vieujean Sophie, Charkaoui Maeva, Richard Nicolas, Wils Pauline, Caron Bénédicte, Amiot Aurélien, Nuzzo Alexandre, Laharie David, Kirchgesner Julien, Uzzan Mathieu, GETAID‐J2J group
Аннотация
BACKGROUND: While three Janus kinase inhibitors (JAKi) have demonstrated efficacy in ulcerative colitis (UC), scarce data exist regarding JAKi intraclass switching.
AIM: To evaluate the effectiveness and safety of a second JAK inhibitor in UC.
METHODS: This was a multicentre, retrospective, observational cohort including patients with moderate to severe UC who received a second-line of JAKi after failure or intolerance of a first. The primary outcome was steroid-free clinical remission (SFCR) at Weeks 8-14, defined as a partial Mayo score of 2 or less with no individual sub-score above 1.
RESULTS: Among the 169 patients from 28 participating centres, 105 received upadacitinib, 54 filgotinib and 10 tofacitinib as a second-line of JAKi. Overall, 81/169 achieved SFCR at Weeks 8-14: 58/105 with upadacitinib, 18/54 with filgotinib and 5/10 with tofacitinib (p = 0.03). In the multivariate analysis, upadacitinib was independently associated with higher odds of SFCR than filgotinib (OR = 3.15, 95% CI [1.52-6.79]). With a median follow-up duration of 96 days, drug persistence at 6 months was 72.8% with upadacitinib, 57.2% with filgotinib and 66.7% with tofacitinib (p = 0.099). 24.3% of patients (41/169) experienced at least one adverse event leading to treatment withdrawal in 9 patients (5%). No cases of death, cancer, or major acute cardiovascular events were reported.
CONCLUSION: A second-line of JAKi provided clinical remission in about half of patients after induction, and was well tolerated.
AIM: To evaluate the effectiveness and safety of a second JAK inhibitor in UC.
METHODS: This was a multicentre, retrospective, observational cohort including patients with moderate to severe UC who received a second-line of JAKi after failure or intolerance of a first. The primary outcome was steroid-free clinical remission (SFCR) at Weeks 8-14, defined as a partial Mayo score of 2 or less with no individual sub-score above 1.
RESULTS: Among the 169 patients from 28 participating centres, 105 received upadacitinib, 54 filgotinib and 10 tofacitinib as a second-line of JAKi. Overall, 81/169 achieved SFCR at Weeks 8-14: 58/105 with upadacitinib, 18/54 with filgotinib and 5/10 with tofacitinib (p = 0.03). In the multivariate analysis, upadacitinib was independently associated with higher odds of SFCR than filgotinib (OR = 3.15, 95% CI [1.52-6.79]). With a median follow-up duration of 96 days, drug persistence at 6 months was 72.8% with upadacitinib, 57.2% with filgotinib and 66.7% with tofacitinib (p = 0.099). 24.3% of patients (41/169) experienced at least one adverse event leading to treatment withdrawal in 9 patients (5%). No cases of death, cancer, or major acute cardiovascular events were reported.
CONCLUSION: A second-line of JAKi provided clinical remission in about half of patients after induction, and was well tolerated.